Trials / Unknown
UnknownNCT05949749
A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average. However, no EBV prophylactic vaccines is clinically available so far, which is largely hampered by the difficulties in selecting optimal vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Epitope exploration | Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls. |
Timeline
- Start date
- 2023-08-25
- Primary completion
- 2024-08-01
- Completion
- 2024-09-30
- First posted
- 2023-07-18
- Last updated
- 2023-09-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05949749. Inclusion in this directory is not an endorsement.